[Our Experience with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma].
Gan To Kagaku Ryoho
; 50(13): 1513-1515, 2023 Dec.
Article
in Ja
| MEDLINE
| ID: mdl-38303325
ABSTRACT
We report our experience with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. METHODS:
Fourteen patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab at our department were retrospectively evaluated for antitumor efficacy and adverse events.RESULTS:
Age ranged from 66-91 years(median 77.5 years), 11 males and 3 females, number of doses ranged from 2-26(median 13), and observation period ranged from 31-790 days (median 427 days). Antitumor efficacy was CR in 3 patients, PR in 3, SD in 6, and PD in 2. One patient with PD died 650 days after the start of treatment, but the others are still alive. Adverse events included proteinuria in 9 patients who discontinued bevacizumab, hypothyroidism requiring levothyroxine sodium hydrate in 7 patients, dermatitis in 2 patients, and colitis requiring hospitalization in 2 patients.DISCUSSION:
Despite the small number of cases, a high antitumor effect was observed with a CR rate of 21%. Although proteinuria and hypothyroidism were observed relatively frequently as adverse events, they were easily controlled and did not pose a major clinical problem.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Antibodies, Monoclonal, Humanized
/
Hypothyroidism
/
Liver Neoplasms
Type of study:
Observational_studies
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
Ja
Journal:
Gan To Kagaku Ryoho
Year:
2023
Document type:
Article
Country of publication: